Thursday, June 05, 2008 4:12:00 PM
From the news, see below for description of this new drug. GTEC has been paying for and supporting its final release, clinical trials etc. since 2006. .. obviously trials are completed and it's time to pay the piper for manufacturing it..
according to the (below news) description, this is some GOOD stuff!!
The Company expects to receive approval of LFAA from China’s State Food and Drug Administration in the first half of calendar year 2009 and to start generating revenue from sales of this drug in the latter half of calendar year 2009. The Company projects that revenue from LFAA sales in Genesis’ fiscal year 2010 (July 2009 through June 2010) will be over $23 million, and that revenues from LFAA sales will be over $35 million in fiscal year 2011, and to continue to grow thereafter. The Company estimates that the profit margin on LFAA sales will be above 80%.
Ligustrazine Ferulic Acid Acetate
Ligustrazine Ferulic Acid Acetate (“LFAA”),
The main indication of the drug is to reduce the plasma viscosity, thereby prevent platelet aggregation; It also provide better treatment for the sequela of a cerebra vascular attack. LFAA is currently the key product beind developed. A detailed explanation of conditions it treats and mechanism of action is followed.
LFAA is a new chemical entity synthesized through a series of chemical combination of ligustrazine and ferulic acid. Some Research indicates that LFAA is more active than ligustrazine alone. Combined ligustrazine and ferulic acid have synergistic effects that enhance the efficacy of ligustrazine as well as reduce its toxicity. At the same time, the new combination can also decrease the disadvantages of ligustrazine, including low bioavailability and a short-half life.
Animal experiments demonstrated that LFAA is 20 times more potent than ligustrazine. In particular, LFAA is 20 times more effective than ligustrazine in inducing endothelial cell replication, 40 times more effective in post-manipulation protection of endothelial cell; six times the effectiveness of ligustrazine in protecting ET from oxidative damage; and four times more effective in preventing cerebral ischemia than ligustrazine.
Most patients suffering from cerebral vascular disease develop thrombosis during the middle to later stages of the disease. Dislodged thrombus can cause damages to the blood vessel and potential embolism, and then result in serious ischemia and downstream tissue damage through hypoxia. LFAA protects and repairs the damaged endothelial cells within the blood vessel; it also has properties that assist with the dissolution of the blood clot.
Corn-fused-us Long-vestor ancient saying: Patience and small movements keep a steady course.
I don't have a humble opinion!
At's ma boy!
according to the (below news) description, this is some GOOD stuff!!
The Company expects to receive approval of LFAA from China’s State Food and Drug Administration in the first half of calendar year 2009 and to start generating revenue from sales of this drug in the latter half of calendar year 2009. The Company projects that revenue from LFAA sales in Genesis’ fiscal year 2010 (July 2009 through June 2010) will be over $23 million, and that revenues from LFAA sales will be over $35 million in fiscal year 2011, and to continue to grow thereafter. The Company estimates that the profit margin on LFAA sales will be above 80%.
Ligustrazine Ferulic Acid Acetate
Ligustrazine Ferulic Acid Acetate (“LFAA”),
The main indication of the drug is to reduce the plasma viscosity, thereby prevent platelet aggregation; It also provide better treatment for the sequela of a cerebra vascular attack. LFAA is currently the key product beind developed. A detailed explanation of conditions it treats and mechanism of action is followed.
LFAA is a new chemical entity synthesized through a series of chemical combination of ligustrazine and ferulic acid. Some Research indicates that LFAA is more active than ligustrazine alone. Combined ligustrazine and ferulic acid have synergistic effects that enhance the efficacy of ligustrazine as well as reduce its toxicity. At the same time, the new combination can also decrease the disadvantages of ligustrazine, including low bioavailability and a short-half life.
Animal experiments demonstrated that LFAA is 20 times more potent than ligustrazine. In particular, LFAA is 20 times more effective than ligustrazine in inducing endothelial cell replication, 40 times more effective in post-manipulation protection of endothelial cell; six times the effectiveness of ligustrazine in protecting ET from oxidative damage; and four times more effective in preventing cerebral ischemia than ligustrazine.
Most patients suffering from cerebral vascular disease develop thrombosis during the middle to later stages of the disease. Dislodged thrombus can cause damages to the blood vessel and potential embolism, and then result in serious ischemia and downstream tissue damage through hypoxia. LFAA protects and repairs the damaged endothelial cells within the blood vessel; it also has properties that assist with the dissolution of the blood clot.
Corn-fused-us Long-vestor ancient saying: Patience and small movements keep a steady course.
I don't have a humble opinion!
At's ma boy!
Corn-fused-us Long-vestor ancient saying: Patience and small movements keep a steady course.
I don't have a humble opinion!
At's ma boy!
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
